so the stock should be in strong hands. Once it gets moving higher, you shouldn’t see a lot of sellers. This is the strategy that helped my subscribers earn a gain of 775% on NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) and more than …
NPS Pharmaceuticals Inc., which agreed to buy a rival, Enzon Pharmaceuticals Inc., for $770 million in stock, said the companies had called off the takeover after failing to agree on a final price. NPS wanted to renegotiate the terms of the …
NPS Pharmaceuticals' shares closed at $33.39 yesterday. Wunderlich initiated coverage on shares of Regions Financial (NYSE: RF) with a “buy” rating. The target price for Regions Financial is set to $12. Regions Financial's stock closed at …
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals ... any shares held by NPS Pharma as treasury stock (other than any shares held in …
This weekend, the big-dog specialty biopharmaceutical company Shire (London Stock Exchange: SHP-GB) announced that it will acquire NPS Pharmaceuticals (NPSP), at a 51 percent premium to where it was trading before. NPS is a …
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ ... previously licensed to Takeda GmbH and the assets related to the two products for common stock valued at $50 million. “The launch of Gattex is off to an …
Drugmaker Shire (SHPG) announced Sunday it had agreed to buy U.S. biotech firm NPS Pharma (NPSP) for $5.2 billion. The all-cash deal valued NPS at $46 per share. NPS stock closed on Friday at $41.91, so it's expected to pop at the …
The deal, in which Alexion will pay cash and stock, values Synageva at more than twice its ... and Ireland-based Shire …
Stock futures are climbing higher ... (ITProPortal) World Business Headlines: Shire has agreed to buy NPS
The Irish drug maker Shire has agreed to acquire NPS Pharmaceuticals for $5.2 billion ... For NPS, the sale comes as the company was enjoying its richest stock market valuation in more than a decade, making it an opportune time to sell.